Creative Biolabs

YSA-Conjugated Liposomes

Datasheet Mdsd
COA

Cat. No.: TDLD-0126-LD322

YSA-Conjugated Liposomes

YSA-Conjugated Liposomes are advanced peptide-functionalized liposomes engineered with YSA Peptide, which specifically binds EphA2 receptors overexpressed in breast, prostate, and pancreatic tumors, enabling targeted delivery of therapeutic cargoes like siRNA, mRNA, DNA, small molecules, and gene editing systems. Applications include targeted cancer therapy, EphA2-specific imaging agent development, and studying EphA2 signaling in tumor biology. Please note that this product is intended for research purposes only.

Inquiry
SPECIFIC INQUIRY
Lipid Formulation:
PEGylation:
Quantity:
Clear All Inquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Payload Type Empty; Custom Cargo
Module Type Peptide
Targeting Module YSA Peptide
Liposome Type Functionalized Liposomes
Target Tumor
Lipid Composition SPC, Chol
PEGylation PEGylated
Application Targeted Delivery
Format Liquid/Lyophilized
Size 50 nm; 100 nm; 200 nm; Others
PDI < 0.3
Zeta Refer to COA
Shipping Gel Pack
Storage Liquid: 2°C- 8°C
Lyophilized: -20°C

Click the button below to contact us or submit your feedback about this product.

Customer Reviews and Q&As
Related Products
EPPT-Conjugated Liposomes (TDLD-0126-LD216) PCM-Conjugated Liposomes (TDLD-0126-LD318) EB1-Conjugated Liposomes (TDLD-0126-LD324) APRPG-Conjugated Liposomes (TDLD-0126-LD314) Control Clodronate Liposomes (Neutral) (TDLD-0126-LD169) c(RGDyK)-Conjugated Liposomes (TDLD-0126-LD205) DiD-Labeled Exosome-Like Liposomes (TDLD-0126-LD172) GNGRGGYC-Conjugated Liposomes (TDLD-0126-LD224)
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations